NCT00259129View on ClinicalTrials.gov

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

53

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

March 31, 2008

Conditions

Neoplasms

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)

Trial Locations (2)

78229

San Antonio

02115

Boston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY